In recent decades, a diverse catalog of CXCR4-specific ligands, including both receptor agonists and antagonists, has been developed, each of them offering unique therapeutic potential for cancer treatment and/or targeted drug delivery (Table 1). This evidence concerns the gene CXCR4 and cancer.